An N6-methyladenosine and target genes-based study on subtypes and prognosis of lung adenocarcinoma

被引:1
|
作者
Chu, Xiao [1 ]
Wang, Weiqing [1 ]
Sun, Zhaoyun [1 ]
Bao, Feichao [2 ]
Feng, Liang [1 ]
机构
[1] Fudan Univ, Peoples Hosp Shanghai 5, Dept Thorac Surg, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Dept Thorac Surg, Affiliated Chest Hosp, Shanghai, Peoples R China
关键词
N-6-methyladenosine (m(6)A); consensus clustering; prognostic score; immune cells; nomogram; TUMOR; EXPRESSION; CELLS; E2F7;
D O I
10.3934/mbe.2022013
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Purpose: Lung adenocarcinoma (LUAD) is a highly lethal subtype of primary lung cancer with a poor prognosis. N6-methyladenosine (m(6)A), the most predominant form of RNA modification, regulates biological processes and has critical prognostic implications for LUAD. Our study aimed to mine potential target genes of m(6)A regulators to explore their biological significance in subtyping LUAD and predicting survival. Methods: Using gene expression data from TCGA database, candidate target genes of m(6)A were predicted from differentially expressed genes (DEGs) in tumor based on M(6)A2 Target database. The survival-related target DEGs identified by Cox-regression analysis was used for consensus clustering analysis to subtype LUAD. Uni-and multi-variable Cox regression analysis and LASSO Cox-PH regression analysis were used to select the optimal prognostic genes for constructing prognostic score (PS) model. Nomogram encompassing PS score and independent prognostic factors was built to predict 3-year and 5-year survival probability. Results: We obtained 2429 DEGs in tumor tissue, within which, 1267 were predicted to m(6)A target genes. A prognostic m(6)A-DEGs network of 224 survival-related target DEGs was established. We classified LUAD into 2 subtypes, which were significantly different in OS time, clinicopathological characteristics, and fractions of 12 immune cell types. A PS model of five genes (C1QTNF6, THSD1, GRIK2, E2F7 and SLCO1B3) successfully split the training set or an independent GEO dataset into two subgroups with significantly different OS time (p < 0.001, AUC = 0.723; p = 0.017, AUC = 0.705).A nomogram model combining PS status, pathologic stage, and recurrence was built, showing good performance in predicting 3-year and 5-year survival probability (C-index = 0.708, 0.723, p-value = 0). Conclusion: Using candidate m(6)A target genes, we obtained two molecular subtypes and designed a reliable five-gene PS score model for survival prediction in LUAD.
引用
收藏
页码:253 / 270
页数:18
相关论文
共 50 条
  • [11] Effects of N6-Methyladenosine Regulators on LAG3 and Immune Infiltrates in Lung Adenocarcinoma
    Wang, Nengchao
    Xu, Yue
    Jin, Linzhi
    Wang, Xiaomin
    Wu, Shouxin
    Wang, Yu
    Zhao, Jiangman
    Zhou, Fuyou
    Ge, Hong
    DISEASE MARKERS, 2022, 2022
  • [12] N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target
    Quan, Chao
    Belaydi, Othmane
    Hu, Jiao
    Li, Huihuang
    Yu, Anze
    Liu, Peihua
    Yi, Zhenglin
    Qiu, Dongxu
    Ren, Wenbiao
    Ma, Hongzhi
    Gong, Guanghui
    Ou, Zhenyu
    Chen, Minfeng
    Sun, Yin
    Chen, Jinbo
    Zu, Xiongbing
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [13] N6-methyladenosine (m6A) regulator expression pattern correlates with the immune landscape in lung adenocarcinoma
    Wan, Rong-Jun
    Bai, Lu
    Jiang, Juan
    Hu, Cheng-Ping
    Chen, Qiong
    Zhao, Bing-Rong
    Zhang, Yan
    Li, Yuan-Yuan
    GENE, 2022, 836
  • [14] Gene and prognostic value of N6-methyladenosine (m6A) modification regulatory factors in lung adenocarcinoma
    Zhang, Di
    Zhang, DanDan
    Wang, Chen
    Yang, XiaoLi
    Zhang, RongQiang
    Li, Qiang
    Xiong, YongMin
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2022, 31 (04) : 354 - 362
  • [15] N6-Methyladenosine Regulators Promote Malignant Progression of Gastric Adenocarcinoma
    Zhao, Yibin
    Yan, Xiao
    Wang, Yu
    Zhou, Juan
    Yu, Yang
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [16] Novel insight of N6-methyladenosine modified subtypes in abdominal aortic aneurysm
    Wang, Kangjie
    Kan, Qinghui
    Ye, Yanchen
    Qiu, Jiachong
    Huang, Lin
    Wu, Ridong
    Yao, Chen
    FRONTIERS IN GENETICS, 2022, 13
  • [17] N6-methyladenosine RNA modifications: a potential therapeutic target for AML
    Hu, Rong
    Liao, Peiyun
    Xu, Binyan
    Qiu, Yingqi
    Zhang, Honghao
    Li, Yuhua
    ANNALS OF HEMATOLOGY, 2024, 103 (08) : 2601 - 2612
  • [18] N6-methyladenosine in macrophage function: a novel target for metabolic diseases
    Zhu, Xiao
    Tang, HaoJun
    Yang, Min
    Yin, Kai
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2023, 34 (02): : 66 - 84
  • [19] RNA N6-methyladenosine: a promising molecular target in metabolic diseases
    Yan Li
    Jiawen Wang
    Chunyan Huang
    Meng Shen
    Huakui Zhan
    Keyang Xu
    Cell & Bioscience, 10
  • [20] RNA N6-methyladenosine: a promising molecular target in metabolic diseases
    Li, Yan
    Wang, Jiawen
    Huang, Chunyan
    Shen, Meng
    Zhan, Huakui
    Xu, Keyang
    CELL AND BIOSCIENCE, 2020, 10 (01):